Skip to content
<title>Channels - Recommendations and Reports: Tularemia Antimicrobial Treatment and Prophylaxis: CDC Recommendations for Naturally Acquired Infections and Bioterrorism Response - United States, 2025 :: FRELIP Discovery
Channels Recommendations and Reports: Tularemia Antimicrobial Treatment and Prophylaxis: CDC Recommendations for Naturally Acquired Infections and Bioterrorism Response - United States, 2025
Recommendations and Reports: Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - CDC Recommendations, United States, 2025
Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis - United States, 2025
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025-26 Influenza Season
Notes from the Field: Increase in Human and Animal Tularemia Cases - Minnesota, 2024
Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025
Kaposi Sarcoma-Associated Herpesvirus Infection and Complications Among Solid Organ Transplant Recipients - United States, January 2021-September 2025
Use of JYNNEOS (Smallpox and Mpox Vaccine, Live, Nonreplicating) for Persons Aged ≥18 Years at Risk for Mpox During an Mpox Outbreak: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023
Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026
Measles Update - United States, January 1-April 17, 2025
Increases in Kratom-Related Reports to Poison Centers - National Poison Data System, United States, 2015-2025
Effectiveness of 2024-2025 COVID-19 Vaccines in Children in the United States - VISION, August 29, 2024-September 2, 2025
Respiratory Virus Activity - United States, July 1, 2024-June 30, 2025
Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025
Mycoplasma pneumoniae Infections in Hospitalized Children - United States, 2018-2024
Increase in Poison Center Reports Linked to Kratom-Containing Kava Products - National Poison Data System, United States, 2000-2025
Notes from the Field: Parvovirus B19 Activity - United States, January 2024-May 2025
Clade II Mpox Infections Among Cruise Ship Passengers and Crew Members - United States, 2024
Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025
COVID-19 Antiviral Prescription Receipt Among Outpatients Aged ≥65 Years - United States, June 1, 2023-September 30, 2025
Human-to-Human Rabies Transmission via Solid Organ Transplantation from a Donor with Undiagnosed Rabies - United States, October 2024-February 2025
Detection of Paraburkholderia in Clinical Specimens Associated with Use of Nonsterile Ultrasound Gel for Percutaneous Procedures - United States, Canada, and Israel, May 2023⎯April 2025
Notes from the Field: Contact Tracing for Monkeypox virus Clade I Cases Associated with Air Travel - United States, November 2024-January 2025
Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - California, October 2025-January 2026
